Stockreport

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent BioPharma, Inc.  (AVBP) 
PDF Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a president [Read more]